# GRID

Source: https://onco.cc/trials/grid/  
OnCo record `grid` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GRID showed that regorafenib held back GIST that had already escaped both imatinib and sunitinib, and gave patients a third line of targeted treatment.

## Summary

GRID randomised 199 patients with metastatic or unresectable gastrointestinal stromal tumour that had progressed on imatinib and sunitinib two to one to regorafenib, a multikinase inhibitor of KIT, PDGFRA and VEGF receptors, or placebo, with crossover at progression. The primary endpoint was progression-free survival.

Regorafenib lengthened progression-free survival several-fold compared with placebo, with disease control in most patients, at the cost of hand-foot skin reaction, hypertension and diarrhoea. Overall survival was confounded by crossover. Regorafenib was approved in the United States in February 2013 as third-line therapy for GIST and held that place until ripretinib arrived in 2020.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-17
- Tags: subtype-trials
- Registry id: NCT01271712
- Phase: 3
- Setting: Metastatic or unresectable gastrointestinal stromal tumour after failure of imatinib and sunitinib: regorafenib against placebo
- Sponsor: Bayer
- Enrolled: 199
- Result: Regorafenib lengthened progression-free survival compared with placebo in GIST after imatinib and sunitinib; approved in February 2013.

## Sources

- ClinicalTrials.gov NCT01271712: https://clinicaltrials.gov/study/NCT01271712

## Connected records

- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/), [Imatinib-resistant GIST](https://onco.cc/cancers/gist-imatinib-resistant/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- drugs: [Regorafenib](https://onco.cc/drugs/regorafenib/)
- companies: [Bayer](https://onco.cc/companies/bayer/)
- people: [George D. Demetri](https://onco.cc/people/george-demetri/)
- key papers: [GRID: regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib](https://onco.cc/key-papers/paper-grid-regorafenib-gist-lancet-2013/)

---
JSON: https://onco.cc/api/v1/entities/grid.json